---
id: 193
title: Prosthetic Joint Infection (PJI)
category: clinical_syndromes
subcategory: bone_joint
tags: [PJI, prosthetic-joint, orthopedic, DAIR, two-stage-exchange, rifampin, biofilm]
difficulty: high
---

## Question

How are prosthetic joint infections managed? Use **"<3wk Acute: DAIR + Rifampin, Chronic: 2-Stage Exchange, *S. aureus* = Cefazolin/Nafcillin + Rifampin"** framework.

## Answer

### **Classification by Timing:**

| Type | Timing Post-Op | Likely Source | Common Organisms |
|------|----------------|---------------|------------------|
| **Early** | <3 months | Intraoperative inoculation | *S. aureus* (MSSA/MRSA), Gram-negatives |
| **Delayed** | 3-24 months | Low-virulence intraoperative | CoNS, *Cutibacterium acnes* |
| **Late** | >24 months | Hematogenous seeding | *S. aureus*, streptococci, Gram-negatives |

### **Diagnosis:**

**Major Criteria (≥1 = PJI):**
1. **Sinus tract** communicating with prosthesis
2. **Purulence** around prosthesis (at surgery)
3. **Same organism** cultured from ≥2 separate samples (joint fluid, tissue)

**Minor Criteria (Score ≥6 = PJI):**
- **Elevated synovial WBC** (>3000 cells/μL)
- **Elevated synovial PMN%** (>80%)
- **Elevated ESR** (>30 mm/h)
- **Elevated CRP** (>10 mg/L)
- **Positive culture** (1 sample)
- **Positive histology** (≥5 PMNs per high-power field)

**Synovial Fluid:**
- **WBC >3000 cells/μL** (chronic) OR **>10,000 cells/μL** (acute) → PJI likely
- **PMN% >80%** → PJI likely
- **Culture:** Aerobic + anaerobic (hold 14 days for slow-growing organisms like *Cutibacterium*)

**Intraoperative Cultures:**
- **≥3-5 tissue samples** (at surgery, before antibiotics)
- **Same organism in ≥2 samples** = PJI

**Imaging:**
- **Loosening on X-ray** (late sign, NOT specific)
- **PET/CT, labeled WBC scan** (if diagnosis uncertain)

### **Surgical Management:**

**DAIR (Debridement, Antibiotics, Implant Retention):**
- **Indications:**
  - **Acute infection** (<3 weeks symptoms) OR **<30 days post-op**
  - **Stable implant** (well-fixed, no loosening)
  - **Healthy soft tissue**
- **Procedure:** Open debridement, exchange modular components (liner, head), retain fixed components (stem, cup)
- **Antibiotics:** Rifampin-based (biofilm penetration)
- **Success rate:** 50-70% (higher for acute, lower for chronic)

**One-Stage Exchange:**
- **Remove prosthesis + reimplant new prosthesis** (same surgery)
- **Indications:** Adequate bone stock, sensitive organism, healthy soft tissue
- **Less common** in US

**Two-Stage Exchange (Gold Standard for Chronic):**
- **Stage 1:** Remove prosthesis, debride, place antibiotic spacer (impregnated with vancomycin + aminoglycoside)
- **IV antibiotics × 4-6 weeks**
- **Stage 2:** Reimplant new prosthesis (after infection cleared, inflammatory markers normalized)
- **Success rate:** 80-90%

**Resection Arthroplasty (Girdlestone):**
- **Remove prosthesis permanently** (no reimplantation)
- **Indications:** Poor surgical candidate, recurrent infection, inadequate bone stock
- **Functional outcome poor** (chronic pain, instability)

**Suppressive Antibiotics (Chronic Suppression):**
- **Indications:** Unfit for surgery, patient refusal, organism susceptible to PO antibiotics
- **Regimen:** Oral antibiotics indefinitely (guided by susceptibilities)
- **Success rate:** Variable (30-70%), risk of resistance

### **Antibiotic Management:**

**Empiric (While Awaiting Cultures):**
- **Vancomycin 15-20 mg/kg IV q8-12h** (MRSA, CoNS) + **cefepime 2g IV q8h** (Gram-negatives)
- OR **vancomycin + piperacillin-tazobactam**

**Pathogen-Directed:**

***S. aureus* (MSSA):**
- **Cefazolin 2g IV q8h** OR **nafcillin 2g IV q4h** × 2-6 weeks
- **THEN rifampin 300-450mg PO BID** + **fluoroquinolone** (levofloxacin 750mg PO daily) OR **minocycline 100mg PO BID** × total 3 months (DAIR) or ≥6 weeks (2-stage after reimplant)

***S. aureus* (MRSA):**
- **Vancomycin** OR **daptomycin 6-10 mg/kg IV daily** × 2-6 weeks
- **THEN rifampin + fluoroquinolone/minocycline** (as above)

**CoNS:**
- **Vancomycin** × 2-6 weeks
- **THEN rifampin + fluoroquinolone** × 3 months

**Streptococci:**
- **Penicillin G 4 million units IV q4h** OR **ceftriaxone 2g IV daily** × 4-6 weeks

**Gram-Negatives:**
- **Ceftriaxone** OR **fluoroquinolone** (based on susceptibilities) × 4-6 weeks
- **Consider adding rifampin** if biofilm-forming

**Anaerobes (***Cutibacterium***):**
- **Penicillin G** OR **clindamycin** OR **ceftriaxone** × 6 weeks

**Duration:**
- **DAIR:** IV × 2-6 weeks → **rifampin-based PO × 3 months** (total)
- **2-stage:** IV × 4-6 weeks (after stage 1), then IV × 2-4 weeks after stage 2
- **Suppression:** Lifelong

### **Key Adjunct: Rifampin:**

**Rationale:**
- **Biofilm penetration** (kills sessile bacteria attached to prosthesis)
- **Essential for implant retention** (DAIR, one-stage)

**Dosing:**
- **300-450mg PO BID**

**Combination Required:**
- **NEVER use rifampin alone** (rapid resistance)
- **Combine with:** Fluoroquinolone (levofloxacin), minocycline, fusidic acid (not available in US), or TMP-SMX

**Timing:**
- **Start after wound healing** (5-7 days post-debridement) - reduces wound complications

## Key Points

### **DAIR vs. 2-Stage:**
- **DAIR:** Acute (<3 weeks symptoms), stable implant → debride + retain + rifampin × 3 months
- **2-Stage:** Chronic (>3 weeks), loosening, failed DAIR → remove + spacer + IV antibiotics → reimplant

### **Rifampin = Essential for Biofilm:**
- **Add rifampin** if implant retained (DAIR, one-stage, suppression)
- **Must combine** (never monotherapy)
- **Start after wound healed** (5-7 days post-op)

### ***S. aureus* = Most Common:**
- **MSSA:** Cefazolin/nafcillin + rifampin + fluoroquinolone
- **MRSA:** Vancomycin/daptomycin + rifampin + fluoroquinolone

### **Synovial Fluid WBC:**
- **>3000 cells/μL** (chronic) OR **>10,000** (acute) + **>80% PMNs** = PJI likely

### **≥3-5 Intraoperative Cultures:**
- **Same organism in ≥2 samples** = diagnostic
- **Hold cultures 14 days** (slow-growing organisms)

### **Clinical Pearls:**
- **Acute (<3 weeks):** DAIR + rifampin-based regimen × 3 months
- **Chronic:** 2-stage exchange (remove → antibiotics 4-6 weeks → reimplant)
- **Rifampin essential** if implant retained (biofilm penetration)
- ***S. aureus*:** Cefazolin (MSSA) or vancomycin (MRSA) + rifampin + fluoroquinolone
- **Synovial fluid:** WBC >3000, PMN >80% = PJI likely

## Sources

- [IDSA: Prosthetic Joint Infection Guidelines 2024]
- [AAOS: PJI Management 2024]

## Media

N/A
